Ovarian Clear Cell Carcinoma Clinical Trial
Official title:
Exploratory Clinical Study of Camrelizumab in Combination With Anlotinib in the Treatment of Patients With Advanced Ovarian Clear Cell Carcinoma
This study is prospective ,open-label, single-center phase II clinical study. Target population is patients with advanced (stage III-IV) ovarian clear cell carcinoma. Study objective is to evaluate effectiveness response of Camrelizumab + anlotinib in subjects with advanced ovarian clear cell carcinoma Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
In this study, eligible subjects were given a combination of carrelizumab and alozantinib at the same time, repeated every 21 days, during treatment based on imaging evaluation of the patient if disease progression, toxicity intolerance, or other reasons specified by the regimen could be terminated. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Recruiting |
NCT05296512 -
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT01914510 -
A Study of ENMD-2076 in Ovarian Clear Cell Cancers
|
Phase 2 | |
| Recruiting |
NCT04104776 -
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
| Recruiting |
NCT03405454 -
A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas
|
Phase 2 | |
| Recruiting |
NCT06065462 -
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05099978 -
Asian Multicenter Prospective Study of ctDNA Sequencing
|
||
| Not yet recruiting |
NCT05759312 -
Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06279104 -
A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary
|
||
| Terminated |
NCT02837991 -
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
|
Phase 1 | |
| Recruiting |
NCT05498597 -
AMT-151 in Patients With Selected Advanced Solid Tumours
|
Phase 1 | |
| Recruiting |
NCT05226507 -
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
|
Phase 1 | |
| Recruiting |
NCT05281471 -
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
|
Phase 3 | |
| Recruiting |
NCT04735861 -
Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02866370 -
Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
|
Phase 2 |